Literature DB >> 11552034

Objective assessment of progression in Huntington's disease: a 3-year follow-up study.

R Reilmann1, F Kirsten, L Quinn, H Henningsen, K Marder, A M Gordon.   

Abstract

Objective measures to assess progression of Huntington's disease (HD) are desirable. The authors have previously found that patients with HD with higher Unified Huntington's Disease Rating Scale (UHDRS) motor scores exhibited higher variability of isometric grip forces while grasping an object. Therefore, the authors assessed grip force variability during this task in 10 HD patients with a 3-year follow-up. Grip force variability increased in all patients at the follow-up. Thus, grip force variability during grasping might be an objective and quantitative measure to assess motor deficits associated with the progression of HD.

Entities:  

Mesh:

Year:  2001        PMID: 11552034     DOI: 10.1212/wnl.57.5.920

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 2.  Basal ganglia mechanisms underlying precision grip force control.

Authors:  Janey Prodoehl; Daniel M Corcos; David E Vaillancourt
Journal:  Neurosci Biobehav Rev       Date:  2009-03-14       Impact factor: 8.989

3.  Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures.

Authors:  Christian Hohenfeld; Imis Dogan; Robin Schubert; Claire Didszun; Ludger Schöls; Matthis Synofzik; Ilaria A Giordano; Thomas Klockgether; Jörg B Schulz; Ralf Reilmann; Kathrin Reetz
Journal:  Cerebellum       Date:  2019-10       Impact factor: 3.847

Review 4.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

5.  Effects of focal hand dystonia on visually guided and internally guided force control.

Authors:  J Prodoehl; D M Corcos; D E Vaillancourt
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-11       Impact factor: 10.154

6.  Quantitative motor assessment of dyskinesias in Parkinson's disease.

Authors:  Eva Schaeffer; Walter Maetzler; Inga Liepelt-Scarfone; Christian Sass; Ralf Reilmann; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2015-02-25       Impact factor: 3.575

7.  Tapping linked to function and structure in premanifest and symptomatic Huntington disease.

Authors:  N Bechtel; R I Scahill; H D Rosas; T Acharya; S J A van den Bogaard; C Jauffret; M J Say; A Sturrock; H Johnson; C E Onorato; D H Salat; A Durr; B R Leavitt; R A C Roos; G B Landwehrmeyer; D R Langbehn; J C Stout; S J Tabrizi; R Reilmann
Journal:  Neurology       Date:  2010-11-10       Impact factor: 9.910

8.  Depressed Synaptic Transmission and Reduced Vesicle Release Sites in Huntington's Disease Neuromuscular Junctions.

Authors:  Ahmad Khedraki; Eric J Reed; Shannon H Romer; Qingbo Wang; William Romine; Mark M Rich; Robert J Talmadge; Andrew A Voss
Journal:  J Neurosci       Date:  2017-07-19       Impact factor: 6.167

9.  Quantitative assessment of motor abnormalities in untreated patients with major depressive disorder.

Authors:  James B Lohr; Todd May; Michael P Caligiuri
Journal:  J Affect Disord       Date:  2012-09-15       Impact factor: 4.839

10.  Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease.

Authors:  A W Michell; A O G Goodman; A H D Silva; S E Lazic; A J Morton; R A Barker
Journal:  J Neurol       Date:  2008-05-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.